Sep 26, 2024 · Nexlizet may cause the following serious side effects. Increased levels of uric acid in your blood (hyperuricemia). This can happen within 4 weeks of starting Nexlizet and can continue …

NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe. The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart procedures, like …

INDICATION NEXLIZET is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic …

Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy. Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe. Bempedoic acid is a member of …

Bempedoic acid, a component of NEXLIZET, is used: to lower the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or heart procedures …

NEXLIZET, which contains an adenosine triphosphate-citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor, is indicated as an adjunct to diet and maximally tolerated statin therapy for the …

The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo …

Jun 16, 2025 · Nexlizet offers a valuable tool for: Preventing progression of atherosclerosis. Reducing cardiovascular risk. Meeting individualized treatment goals set by physicians. By adding Nexlizet to a …

Mar 9, 2020 · Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary …

Jun 30, 2024 · What is Nexlizet used for? Nexlizet (bempedoic acid/ ezetimibe) is commonly used for the following conditions. To lower the risk of heart attack and certain heart procedures like stent …